JP2021035395A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021035395A5 JP2021035395A5 JP2020199336A JP2020199336A JP2021035395A5 JP 2021035395 A5 JP2021035395 A5 JP 2021035395A5 JP 2020199336 A JP2020199336 A JP 2020199336A JP 2020199336 A JP2020199336 A JP 2020199336A JP 2021035395 A5 JP2021035395 A5 JP 2021035395A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- domain
- chain constant
- constant domain
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims 17
- 229920001184 polypeptide Polymers 0.000 claims 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 14
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 claims 12
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 11
- 102000035160 transmembrane proteins Human genes 0.000 claims 7
- 108091005703 transmembrane proteins Proteins 0.000 claims 7
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 238000006471 dimerization reaction Methods 0.000 claims 3
- 230000019491 signal transduction Effects 0.000 claims 3
- 230000002269 spontaneous effect Effects 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 1
- 101710160107 Outer membrane protein A Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000004186 co-expression Effects 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000006801 homologous recombination Effects 0.000 claims 1
- 238000002744 homologous recombination Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022178045A JP2022190153A (ja) | 2015-08-20 | 2022-11-07 | キメラサイトカイン受容体 |
| JP2025047074A JP2025089403A (ja) | 2015-08-20 | 2025-03-21 | キメラサイトカイン受容体 |
| JP2025047075A JP2025089404A (ja) | 2015-08-20 | 2025-03-21 | キメラサイトカイン受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1514875.2A GB201514875D0 (en) | 2015-08-20 | 2015-08-20 | Receptor |
| GB1514875.2 | 2015-08-20 | ||
| JP2019113625A JP6979423B2 (ja) | 2015-08-20 | 2019-06-19 | キメラサイトカイン受容体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019113625A Division JP6979423B2 (ja) | 2015-08-20 | 2019-06-19 | キメラサイトカイン受容体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022178045A Division JP2022190153A (ja) | 2015-08-20 | 2022-11-07 | キメラサイトカイン受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021035395A JP2021035395A (ja) | 2021-03-04 |
| JP2021035395A5 true JP2021035395A5 (enExample) | 2021-09-30 |
| JP7603426B2 JP7603426B2 (ja) | 2024-12-20 |
Family
ID=54292003
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018509549A Withdrawn JP2018523485A (ja) | 2015-08-20 | 2016-08-19 | キメラサイトカイン受容体 |
| JP2019113625A Active JP6979423B2 (ja) | 2015-08-20 | 2019-06-19 | キメラサイトカイン受容体 |
| JP2020199336A Active JP7603426B2 (ja) | 2015-08-20 | 2020-12-01 | キメラサイトカイン受容体 |
| JP2022178045A Withdrawn JP2022190153A (ja) | 2015-08-20 | 2022-11-07 | キメラサイトカイン受容体 |
| JP2025047075A Pending JP2025089404A (ja) | 2015-08-20 | 2025-03-21 | キメラサイトカイン受容体 |
| JP2025047074A Pending JP2025089403A (ja) | 2015-08-20 | 2025-03-21 | キメラサイトカイン受容体 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018509549A Withdrawn JP2018523485A (ja) | 2015-08-20 | 2016-08-19 | キメラサイトカイン受容体 |
| JP2019113625A Active JP6979423B2 (ja) | 2015-08-20 | 2019-06-19 | キメラサイトカイン受容体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022178045A Withdrawn JP2022190153A (ja) | 2015-08-20 | 2022-11-07 | キメラサイトカイン受容体 |
| JP2025047075A Pending JP2025089404A (ja) | 2015-08-20 | 2025-03-21 | キメラサイトカイン受容体 |
| JP2025047074A Pending JP2025089403A (ja) | 2015-08-20 | 2025-03-21 | キメラサイトカイン受容体 |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US10800854B2 (enExample) |
| EP (3) | EP3438123A1 (enExample) |
| JP (6) | JP2018523485A (enExample) |
| KR (2) | KR102669749B1 (enExample) |
| CN (2) | CN110724200B (enExample) |
| AU (1) | AU2016308618B2 (enExample) |
| BR (1) | BR112018003308A2 (enExample) |
| CA (2) | CA2995785A1 (enExample) |
| CL (2) | CL2018000415A1 (enExample) |
| GB (1) | GB201514875D0 (enExample) |
| HK (1) | HK1252161A1 (enExample) |
| IL (2) | IL270207B2 (enExample) |
| MX (2) | MX2018002042A (enExample) |
| RU (1) | RU2018109350A (enExample) |
| SG (1) | SG10201909759UA (enExample) |
| WO (1) | WO2017029512A1 (enExample) |
| ZA (1) | ZA201904156B (enExample) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3653212B1 (en) | 2012-12-20 | 2023-04-26 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| KR20210014210A (ko) | 2014-05-15 | 2021-02-08 | 내셔널 유니버시티 오브 싱가포르 | 변형된 천연 살해 세포 및 그의 용도 |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201518816D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| IL309526B2 (en) | 2016-11-17 | 2025-02-01 | 2Seventy Bio Inc | TGFBeta signal converter |
| AU2017378153B2 (en) * | 2016-12-13 | 2024-03-28 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo |
| US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| ES3010559T3 (en) | 2017-02-28 | 2025-04-03 | Endocyte Inc | Compositions and methods for car t cell therapy |
| CA3056439A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy |
| EP3679145A2 (en) * | 2017-09-08 | 2020-07-15 | Poseida Therapeutics, Inc. | Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression |
| GB201714718D0 (en) | 2017-09-13 | 2017-10-25 | Autolus Ltd | Cell |
| GB201716728D0 (en) | 2017-10-12 | 2017-11-29 | Autolus Ltd | Cell |
| GB201717524D0 (en) | 2017-10-25 | 2017-12-06 | Autolus Ltd | Vectors |
| GB201719557D0 (en) * | 2017-11-24 | 2018-01-10 | Autolus Ltd | Polypeptide |
| EP3723787A4 (en) * | 2017-12-14 | 2021-09-01 | Bluebird Bio, Inc. | DARIC INTERLEUKIN RECEPTORS |
| AU2019209428B2 (en) | 2018-01-22 | 2025-06-26 | Endocyte, Inc. | Methods of use for CAR T cells |
| GB201801831D0 (en) * | 2018-02-05 | 2018-03-21 | Autolus Ltd | Chimeric receptor |
| CA3090089A1 (en) | 2018-02-06 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| TW202000229A (zh) | 2018-02-23 | 2020-01-01 | 美商安德賽特公司 | Car t細胞療法之順序方法 |
| EP3759132A1 (en) * | 2018-03-02 | 2021-01-06 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| WO2019200056A2 (en) | 2018-04-12 | 2019-10-17 | Vivo-Til Therapeutics Inc. | Viral vectors and packaging cell lines |
| CN112041436A (zh) | 2018-04-27 | 2020-12-04 | 西雅图儿童医院（Dba西雅图儿童研究所） | 雷帕霉素抗性细胞 |
| EP3806904A4 (en) * | 2018-06-18 | 2022-04-27 | Eureka Therapeutics, Inc. | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED CONSTRUCTS AND USES THEREOF |
| CN110615843B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含第三信号受体的嵌合抗原受体及其应用 |
| GB201812474D0 (en) | 2018-07-31 | 2018-09-12 | Autolus Ltd | Nucleic acid construct |
| US12486514B2 (en) * | 2018-08-29 | 2025-12-02 | National University Of Singapore | Method to specifically stimulate survival and expansion of genetically-modified immune cells |
| PL3856775T3 (pl) | 2018-09-27 | 2025-06-09 | Autolus Limited | Chimeryczny receptor antygenowy |
| US20200147137A1 (en) * | 2018-11-08 | 2020-05-14 | WUGEN, Inc. | Compositions and methods for treatment of cancer |
| CN111378046B (zh) * | 2018-12-27 | 2024-03-15 | 上海细胞治疗集团有限公司 | 一种免疫效应细胞转换受体 |
| CA3129862A1 (en) * | 2019-03-01 | 2020-09-10 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a pd-1 ectodomain |
| CN113508128B (zh) | 2019-03-01 | 2025-11-04 | 艾洛基治疗公司 | 组成型活性嵌合细胞因子受体 |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| US20220145325A1 (en) * | 2019-03-08 | 2022-05-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| GB201903237D0 (en) | 2019-03-08 | 2019-04-24 | Autolus Ltd | Method |
| EP3714941A1 (en) | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| GB201911187D0 (en) | 2019-08-05 | 2019-09-18 | Autolus Ltd | Receptor |
| EP4021582A1 (en) | 2019-08-30 | 2022-07-06 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors comprising tgf beta binding domains |
| AU2020346824A1 (en) * | 2019-09-11 | 2022-03-31 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric orthogonal receptor proteins and methods of use |
| KR102275668B1 (ko) * | 2019-09-26 | 2021-07-12 | 충북대학교 산학협력단 | 면역신호의 변환이 가능한 키메릭 사이토카인 수용체, 이를 발현하는 면역세포 및 이의 항암 용도 |
| JP2022551909A (ja) * | 2019-10-10 | 2022-12-14 | ブライオロジクス インコーポレイテッド | ブリオスタチンによる腫瘍関連抗原の誘導方法 |
| EP4100428A4 (en) | 2020-02-04 | 2024-03-06 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | CHIMERIC ANTI-DINITROPHENOL ANTIGEN RECEPTORS |
| TWI894211B (zh) | 2020-02-24 | 2025-08-21 | 美商異基因治療有限公司 | 具有增強活性之bcma car-t細胞 |
| TW202146431A (zh) | 2020-02-25 | 2021-12-16 | 英商圭爾醫療有限公司 | 用於經工程化細胞之嵌合受體 |
| CA3172691A1 (en) | 2020-03-31 | 2021-10-07 | Cameron J. Turtle | Chimeric antigen receptors targeting cd33 |
| EP4126925A4 (en) * | 2020-03-31 | 2024-07-24 | Fred Hutchinson Cancer Center | CHIMERIC ANTIGEN RECEPTORS TARGETED AGAINST CD33 |
| GB202101491D0 (en) | 2021-02-03 | 2021-03-17 | Autolus Ltd | Molecule |
| WO2021205175A1 (en) | 2020-04-09 | 2021-10-14 | Autolus Limited | Molecule |
| GB202007044D0 (en) | 2020-05-13 | 2020-06-24 | Autolus Ltd | Method |
| CN113201063B (zh) * | 2020-07-31 | 2022-04-19 | 北京市神经外科研究所 | IL7Rα的截短体及其在制备治疗肿瘤的药物中的用途 |
| WO2022037562A1 (en) * | 2020-08-17 | 2022-02-24 | Nanjing Legend Biotech Co., Ltd. | Engineered immunoresponsive cells and uses thereof |
| CN112961248B (zh) * | 2021-02-22 | 2022-03-18 | 广州百暨基因科技有限公司 | 共表达IL-7和CCR2b的嵌合抗原受体融合蛋白及其应用 |
| CN113072648B (zh) * | 2021-06-04 | 2021-08-24 | 诺未科技（北京）有限公司 | 一种靶向afp的肝癌疫苗 |
| CN113416708A (zh) * | 2021-06-10 | 2021-09-21 | 深圳市先康达生命科学有限公司 | 一种表达细胞因子受体融合型嵌合抗原受体的免疫细胞及其应用 |
| KR102827437B1 (ko) * | 2021-08-30 | 2025-07-02 | 연세대학교 산학협력단 | 림프종의 예방 또는 치료를 위한 림프종 세포 특이적 약물 전달체 및 이의 제조방법 |
| AU2022347445A1 (en) * | 2021-09-17 | 2024-04-04 | Parker Institute For Cancer Immunotherapy | Switch receptors using il-9 signaling domains |
| GB202115329D0 (en) | 2021-10-25 | 2021-12-08 | Autolus Ltd | Chimeric cytokine receptor |
| EP4519294A1 (en) * | 2022-05-04 | 2025-03-12 | Earli Inc. | Methods using surface-expressable activatable epitopes to localize and/or treat diseased cells |
| CN119768508A (zh) * | 2022-07-11 | 2025-04-04 | 索诺玛生物治疗公司 | 重组细胞因子受体及其使用方法 |
| WO2024044768A2 (en) * | 2022-08-26 | 2024-02-29 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric cytokine receptors and methods of use |
| CN117402262A (zh) * | 2022-10-19 | 2024-01-16 | 上海君赛生物科技有限公司 | 基于lag3的嵌合免疫细胞辅助受体及其用途 |
| EP4630446A1 (en) * | 2022-12-06 | 2025-10-15 | Dynamic Cell Therapies, Inc. | Engineered switches for immune cell activity and methods of use thereof |
| IL322256A (en) | 2023-01-23 | 2025-09-01 | Medizinische Hochschule Hannover | Anti-ENTPD3 chimeric antigen receptor |
| EP4403580A1 (en) | 2023-01-23 | 2024-07-24 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| IL322333A (en) | 2023-02-07 | 2025-09-01 | Quell Therapeutics Ltd | Culture method for TREG cells |
| EP4420676A1 (en) | 2023-02-24 | 2024-08-28 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024175805A1 (en) | 2023-02-24 | 2024-08-29 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| JP2026507228A (ja) | 2023-03-03 | 2026-02-27 | アーセナル バイオサイエンシズ インコーポレイテッド | Ｐｓｍａ及びｃａ９を標的とするシステム |
| WO2024194605A1 (en) | 2023-03-17 | 2024-09-26 | Quell Therapeutics Limited | Treg therapy |
| CN120917054A (zh) | 2023-03-20 | 2025-11-07 | 奥托路斯有限公司 | 嵌合细胞因子受体，其包含截短的IL2Rβ和IL2Rγ |
| EP4434539A1 (en) | 2023-03-20 | 2024-09-25 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| CN121586582A (zh) | 2023-03-20 | 2026-02-27 | 汉诺威医学院 | 嵌合抗原受体 |
| WO2024238287A1 (en) * | 2023-05-12 | 2024-11-21 | Chimeris Uk Ltd. | Dual blocking and chimeric cytokine receptor |
| GB202309704D0 (en) | 2023-06-27 | 2023-08-09 | Autolus Ltd | Chimeric transmembrane protein |
| GB202312009D0 (en) | 2023-08-04 | 2023-09-20 | Autolus Ltd | Methods and cell compositions |
| WO2025189046A2 (en) * | 2024-03-06 | 2025-09-12 | The Johns Hopkins University | Pantigen specific cytokine receptor stimulation of immune cell function |
| WO2025221843A1 (en) * | 2024-04-17 | 2025-10-23 | Baylor College Of Medicine | Methods and compositions for suppressing immune cell activation |
| WO2026008994A1 (en) | 2024-07-04 | 2026-01-08 | Quell Therapeutics Limited | Expression construct |
| GB202411558D0 (en) | 2024-08-06 | 2024-09-18 | Quell Therapeutics Ltd | Culture method |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU683073B2 (en) | 1993-06-07 | 1997-10-30 | Amgen, Inc. | Hybrid receptor molecules |
| GB9526131D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
| AU758949B2 (en) * | 1998-05-19 | 2003-04-03 | Avidex Limited | Multivalent T cell receptor complexes |
| ATE432942T1 (de) * | 2001-03-09 | 2009-06-15 | Zymogenetics Inc | Löslicher heterodimerer cytokinrezeptor |
| CN1659274A (zh) * | 2002-04-19 | 2005-08-24 | 津莫吉尼蒂克斯公司 | 细胞因子受体 |
| JP2004113062A (ja) | 2002-09-25 | 2004-04-15 | Teruyuki Nagamune | キメラ受容体を有する動物細胞とその利用 |
| CN101027079B (zh) * | 2004-10-12 | 2011-08-17 | 美国蛋白质公司 | 嵌合蛋白 |
| WO2007115230A2 (en) | 2006-03-30 | 2007-10-11 | University Of Medicine And Dentistry Of New Jersey | A strategy for homo- or hetero-dimerization of various proteins in solutions and in cells |
| WO2008045437A2 (en) | 2006-10-09 | 2008-04-17 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| US20110038865A1 (en) * | 2007-06-26 | 2011-02-17 | University Of Miami | Antibody- endostatin fusion protein and its variants |
| WO2010085660A2 (en) | 2009-01-23 | 2010-07-29 | Roger Williams Hospital | Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
| EP2478110B1 (en) | 2009-09-16 | 2016-01-06 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
| NZ616405A (en) | 2011-04-08 | 2015-11-27 | Baylor College Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| RU2522004C2 (ru) | 2012-04-10 | 2014-07-10 | Владимир Константинович Боженко | Одноцепочечное антитело к раково-эмбриональному антигену, химерный мономолекулярный т-клеточный рецептор, вектор и клетка-хозяин для обеспечения экспрессии такого рецептора и способ диагностики или лечения. |
| US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| MA41538A (fr) * | 2014-10-17 | 2017-12-26 | Baylor College Medicine | Cellules immunitaires bipartites et tripartites de signalisation |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201518817D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Cell |
| GB201518816D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| GB201719557D0 (en) | 2017-11-24 | 2018-01-10 | Autolus Ltd | Polypeptide |
| PL3856775T3 (pl) | 2018-09-27 | 2025-06-09 | Autolus Limited | Chimeryczny receptor antygenowy |
-
2015
- 2015-08-20 GB GBGB1514875.2A patent/GB201514875D0/en not_active Ceased
-
2016
- 2016-08-19 CN CN201911010436.8A patent/CN110724200B/zh active Active
- 2016-08-19 CN CN201680046834.3A patent/CN108350047A/zh active Pending
- 2016-08-19 JP JP2018509549A patent/JP2018523485A/ja not_active Withdrawn
- 2016-08-19 BR BR112018003308-1A patent/BR112018003308A2/pt not_active Application Discontinuation
- 2016-08-19 KR KR1020187007751A patent/KR102669749B1/ko active Active
- 2016-08-19 MX MX2018002042A patent/MX2018002042A/es unknown
- 2016-08-19 RU RU2018109350A patent/RU2018109350A/ru unknown
- 2016-08-19 EP EP18189793.5A patent/EP3438123A1/en active Pending
- 2016-08-19 AU AU2016308618A patent/AU2016308618B2/en active Active
- 2016-08-19 CA CA2995785A patent/CA2995785A1/en not_active Abandoned
- 2016-08-19 CA CA3091907A patent/CA3091907C/en active Active
- 2016-08-19 MX MX2019013204A patent/MX421045B/es unknown
- 2016-08-19 SG SG10201909759U patent/SG10201909759UA/en unknown
- 2016-08-19 WO PCT/GB2016/052564 patent/WO2017029512A1/en not_active Ceased
- 2016-08-19 EP EP23216609.0A patent/EP4338756A3/en active Pending
- 2016-08-19 HK HK18111554.5A patent/HK1252161A1/zh unknown
- 2016-08-19 US US15/753,486 patent/US10800854B2/en active Active
- 2016-08-19 IL IL270207A patent/IL270207B2/en unknown
- 2016-08-19 EP EP16756758.5A patent/EP3337814A1/en active Pending
- 2016-08-19 KR KR1020247017118A patent/KR20240093884A/ko active Pending
-
2018
- 2018-01-30 IL IL257234A patent/IL257234A/en unknown
- 2018-02-15 CL CL2018000415A patent/CL2018000415A1/es unknown
- 2018-08-27 US US16/113,224 patent/US10800855B2/en active Active
-
2019
- 2019-04-23 CL CL2019001107A patent/CL2019001107A1/es unknown
- 2019-06-19 JP JP2019113625A patent/JP6979423B2/ja active Active
- 2019-06-26 ZA ZA2019/04156A patent/ZA201904156B/en unknown
-
2020
- 2020-08-20 US US16/998,756 patent/US11479613B2/en active Active
- 2020-08-20 US US16/999,012 patent/US11479614B2/en active Active
- 2020-12-01 JP JP2020199336A patent/JP7603426B2/ja active Active
-
2022
- 2022-07-26 US US17/815,110 patent/US12234295B2/en active Active
- 2022-11-07 JP JP2022178045A patent/JP2022190153A/ja not_active Withdrawn
-
2025
- 2025-01-21 US US19/033,252 patent/US20250333538A1/en active Pending
- 2025-03-21 JP JP2025047075A patent/JP2025089404A/ja active Pending
- 2025-03-21 JP JP2025047074A patent/JP2025089403A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021035395A5 (enExample) | ||
| JP2019150066A5 (enExample) | ||
| JP7266117B2 (ja) | クローディン１８．２を標的とする抗体又はキメラ抗原受容体 | |
| CN110662560B (zh) | 改进的抗原结合受体 | |
| CN110121505B (zh) | 嵌合抗原受体和表达其的自然杀伤细胞 | |
| CN109069537B (zh) | 共刺激结构域中具有重复结合基序的car | |
| JP2018523485A5 (enExample) | ||
| JP2019535262A5 (enExample) | ||
| US12090171B2 (en) | Antibody or antigen binding fragment thereof for specifically recognizing B cell malignancy, chimeric antigen receptor comprising same and use thereof | |
| JP2018523484A5 (enExample) | ||
| JP2018532407A5 (enExample) | ||
| CN109789164B (zh) | 具有gitr胞内结构域作为共刺激结构域的嵌合抗原受体 | |
| BR112021007334A2 (pt) | anticorpo anti-l1cam ou fragmento de ligação ao antígeno do mesmo, e receptor de antígeno quimérico compreendendo o mesmo | |
| KR20230010188A (ko) | 항-IL13Rα2 항체, 이의 항원 결합 단편 및 용도 | |
| CN114149506B (zh) | 一种抗cd22抗体及其应用 | |
| JP7394067B2 (ja) | がん患者における腫瘍抗原を検出するための診断アッセイ | |
| JP2021514648A (ja) | 新規の標的抗原結合部分のための特異性アッセイ | |
| KR20230022411A (ko) | 키메라 항원 수용체 스페이서 | |
| JP2024543152A (ja) | 改善された抗原結合受容体 | |
| EP3730519B1 (en) | Antibody or antigen-binding fragment thereof that specifically recognizes b cell malignancies, chimeric antigen receptor comprising same, and uses thereof | |
| CN115466328B (zh) | 抗pd-1人源化抗体或其抗原结合片段及其应用 | |
| JP2023520658A (ja) | 抗ｔｎ－ｍｕｃ１キメラ抗原受容体 | |
| JP2025512797A (ja) | 改善されたキメラ受容体 | |
| CN116217732A (zh) | 靶向cd22和cd19的双特异性抗体及其嵌合抗原受体和应用 | |
| CN113874396A (zh) | 包含抗间皮素抗体、抗cd3抗体或抗egfr抗体的融合蛋白、包含所述融合蛋白的双特异性或三特异性抗体，及其用途 |